Withanolide A and Asiatic Acid Modulate Multiple Targets Associated with Amyloid-β Precursor Protein Processing and Amyloid-β Protein Clearance

Alzheimer's disease (AD) is a progressive, neurodegenerative disease histochemically characterized by extracellular deposits of amyloid beta (A beta) protein and intracellular neurofibrillary tangles of hyperphosphorylated tau protein. AD is considered to be a complex, multi factorial syndrome, with numerous causal factors contributing to its pathogenesis. Thus, for any novel therapeutic molecule to have a disease-modifying effect on AD, it must be able to modulate multiple, synergistic targets simultaneously. In this context, we have studied two compounds of plant origin [withanolide A (1) and asiatic acid (2)] for their potential activities against multiple targets associated with A beta pathways (BACEI, ADAM10, IDE, and NEP). BACEI is a rate-limiting enzyme in the production of A beta from amyloid-beta precursor protein (APPP), while ADAM 10 is involved in non-amyloidogenic processing of A beta PP. IDE and NEP are two of the prominent enzymes in in effectively degrading A beta. It was found that both 1 and 2 significantly down-regulated BACEI and also up-regulated ADAM10 in primary rat cortical neurons. In addition, 1 significantly up-regulated IDE levels. which may help in degrading excess A beta from the AD brain. On the basis of the data obtained, the two multifunctional compounds may prove valuable in developing novel, effective therapeutics for the prevention and treatment of AD-associated amyloid pathology.